Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
A live audio webcast will be available within the Investor and News section of the Rubius Therapeutics’ website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on Twitter.
+1 (973) 271-6085
Vice President, Corporate Communications and Investor Relations
+1 (617) 229-6122
Source: Rubius Therapeutics